Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Phase II Chemotherapy with Deazauridine for Acute Myelogenous or Lymphocytic Leukemia

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Closed

15 and over

MDA-DT-7830

Objectives

I.  Determine the efficacy of deazauridine administered by continuous 
intravenous infusion to patients with acute myelogenous and acute lymphocytic 
leukemia.
II.  Determine the qualitative and quantitative toxicity of deazauridine 
administered in this fashion.
III.  Determine duration of response and duration of survival of patients 
receiving this therapy.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients 15 years old or more with 
histologically proven active acute leukemia not eligible for higher priority 
therapy.  Patients must have discontinued prior therapy for 2 weeks prior to 
entry, and must have recovered from any associated toxicity.

Expected Enrollment

Protocol closed 12/79.

Outline

Nonrandomized study.
Single-agent Chemotherapy.  Deazauridine, NSC-126849.

Trial Contact Information

Trial Lead Organizations

M. D. Anderson Cancer Center at University of Texas

Eugene M. McKelvey, MD, Protocol chair
Ph: 713-792-2570; 800-392-1611

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.